[{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts","type":"changed","fields":[{"field":"tldr","before":"\"Japan's guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for its own approvals through PMDA.\"","after":"\"The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resectio..."}]},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"url"},{"field":"holds"},{"field":"maintainer"},{"field":"license"},{"field":"tldr"},{"field":"summary"},{"field":"related"},{"field":"institutions"},{"field":"links"},{"field":"tags"}]}]